Oculis Holding AG (OCS) Amortization of Deferred Charges (2022 - 2024)
Oculis Holding AG's (OCS) quarterly Amortization of Deferred Charges came in at $50410.0 in Q1 2024, up 66.52% year-on-year from $30272.6 in Q2 2023, and down 0.63% quarter-over-quarter from $50731.0 in Q4 2023.
Oculis Holding AG (OCS) Amortization of Deferred Charges (2022 - 2024) Analysis & Trends
Oculis Holding AG's Amortization of Deferred Charges history runs 3 years deep, the most recent figure standing at $50410.0 for Q1 2024.
- On a quarterly basis, Amortization of Deferred Charges rose 66.52% year-over-year to $50410.0 in Q1 2024; TTM through Mar 2024 was $201003.6, a N/A change from a year earlier, with the FY2024 full-year figure at $310319.5, up 72.04% from the prior year.
- Amortization of Deferred Charges fell to $50410.0 in Q1 2024 per OCS's latest filing, from $50731.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $50731.0 in Q4 2023 and bottomed at $30272.6 in Q1 2023.
- The 3-year median for Amortization of Deferred Charges is $49814.7 (2023), against an average of $45629.0.
- Across the five-year window, Amortization of Deferred Charges rose 11.07% in 2023 and surged 66.52% in 2024, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $45673.0 in 2022, then climbed by 11.07% to $50731.0 in 2023, then slipped by 0.63% to $50410.0 in 2024.
- Per Business Quant, the three latest OCS Amortization of Deferred Charges figures stand at $50410.0 (Q1 2024), $50731.0 (Q4 2023), and $49814.7 (Q3 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 50,410.02 |
| Mar 31, 2024 | 50,410.02 |
| Dec 31, 2023 | 50,730.95 |
| Dec 31, 2023 | 50,730.95 |
| Sep 30, 2023 | 49,814.71 |
| Sep 30, 2023 | 49,814.71 |
| Jun 30, 2023 | 50,047.90 |
| Jun 30, 2023 | 50,047.90 |
| Mar 31, 2023 | 30,272.55 |
| Mar 31, 2023 | 30,272.55 |
| Dec 31, 2022 | 45,672.96 |
| Dec 31, 2022 | 45,672.96 |
| Sep 30, 2022 | 42,453.72 |
| Sep 30, 2022 | 42,453.72 |